ERBB2 and neoplasm: In breast cancer, PD-1/PD-L1 may affect various signaling pathways, such as PTEN/PIK3CA, ERBB2 and STAT3, affecting various biological processes of tumor cells and the interaction between tumor cells and immune cells [48].